Scivision Biotech (TPE:1786) Research & Development: NT$93.2 Mil (TTM As of Dec. 2025)


TPE:1786 Scivision Biotech Inc TPE:1786
80 GF Score
Price NT$53.50
GF Value NT$115.23
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Scivision Biotech Research & Development?

Scivision Biotech TPE:1786 -0.56% 80 Research & Development is NT$93.2 Mil as of Dec. 2025. GuruFocus rates TPE:1786 with a GF Score™ of 80/100 and a GF Value™ of NT$115.23 (Possible Value Trap). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Scivision Biotech's Research & Development for the three months ended in Dec. 2025 was NT$32.4 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was NT$93.2 Mil.

Scivision Biotech  (TPE:1786) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Scivision Biotech Research & Development Related Terms

Scivision Biotech Research & Development Historical Data

* Premium members only.

The historical data trend for Scivision Biotech's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scivision Biotech Research & Development Chart

Scivision Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 65.94 52.46 53.42 60.71 93.19

Scivision Biotech Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.06 18.87 20.67 21.26 32.39
TPE:1786
80GF Score
Scivision Biotech Inc TPE:1786
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scivision Biotech Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$93.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of NT$93.2 Mil mean?
Scivision Biotech (TPE:1786) has a Research & Development of NT$93.2 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Scivision Biotech and its competitors.
Is Scivision Biotech's Research & Development too high?
Scivision Biotech's current Research & Development is NT$93.2 Mil. Overall, Scivision Biotech has a GF Score™ of 80/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Scivision Biotech's Research & Development compare to ISRG and BDX?
Scivision Biotech's Research & Development of NT$93.2 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Scivision Biotech and its competitors. Scivision Biotech's current Research & Development is NT$93.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scivision Biotech stock overvalued right now?
Based on GuruFocus' analysis, Scivision Biotech (TPE:1786) is currently considered Possible Value Trap. The stock's GF Value™ is NT$115.23, compared to a current price of NT$53.50 — trading 53.6% below its estimated fair value. The current Research & Development is NT$93.2 Mil. Scivision Biotech's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Scivision Biotech (TPE:1786), the current Research & Development is NT$93.2 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Scivision Biotech (TPE:1786) Overvalued in 2026?

Based on GuruFocus' analysis, Scivision Biotech stock appears to be undervalued. The current stock price of NT$53.50 is trading 53.6% below its estimated GF Value™ of NT$115.23. GuruFocus considers Scivision Biotech to be Possible Value Trap.

Key valuation signals for TPE:1786:

  • Research & Development: NT$93.2 Mil
  • GF Value™: NT$115.23 vs. price of NT$53.50 (53.6% below fair value)
  • GF Score™: 80/100 with 4 warning signs

No single metric tells the full story. See the TPE:1786 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Scivision Biotech Business Description

Address No. 1, South 1st Road, Qianzhen District, Kaohsiung, TWN, 806
Scivision Biotech Inc is engaged in the manufacturing and distribution of hyaluronic acid medical supplies in Taiwan. It offers medical devices, including absorbable adhesion barriers, dermal implants, synovial fluid supplements, and intravesical instillation.
80GF Score

Get the complete analysis for TPE:1786

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$53.50
Price
NT$115.23
GF Value